Investment
Features
FeesSafety
Academy
More
Pluang+

Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Company Fundamentals
06 Oct 2026
Alex Lavoie
View Source
Bullish
Constellation Brands beats earnings and revenue estimates with strong beer and spirits sales.

Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales, driving the better-than-expected financial results. With a trailing price-to-earnings ratio of 10.39, the strong sales growth highlights the company's solid market performance and potential for continued profitability.

Constellation Brands' earnings beat estimates, with strong sales growth in beer and wine and spirits. For readers following the Consumer Staples sector, here is Pluang's market snapshot as of Oct 07, 2026 03:16 WIB: Of 51 priced US Consumer Staples stocks tradable on Pluang, 32 rose and 18 fell today. Notable movers include OTLY at USD 10.90 with a 1-day change of -4.13%, LW at USD 45.05 with +3.33%, and COUR at USD 5.17 with +3.09%.

More News

Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands to report Q1 2027 results with expected revenue growth and ongoing losses

Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...

Company Fundamentals
Neutral
28 minutes ago
Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

Five stocks jump 21%-53% on news of acquisitions, blockchain, AI, and federal financing.

On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...

Market News
Bullish
28 minutes ago
Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

Five stocks drop sharply on Oct 6, led by ArriVent BioPharma after lung cancer drug trial failure.

On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...

Market News
Bearish
28 minutes ago
Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore raises Marvell's price target to $433 on strong AI and data center growth forecasts.

Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...

Analyst Insights
Bullish
1 hour ago
Neogen beats earnings estimates but stock falls after FDA warning on recalled product.

Neogen beats earnings estimates but stock falls after FDA warning on recalled product.

Neogen reported earnings per share of $0.08 and revenue of $222.8 million, both exceeding analyst expectations. The company also announced a strategic partnership with Hinalea Imaging Corp. to develop digital food safety tools. However, Neogen's stoc...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App